Physician profile
Philip Abela
NPI 1528130374
$173.26
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.37 · 2022: $18.09 · 2023: $45.17 · 2024: $98.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $143.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $64.28 | 2024 | Arexvy, Shingrix |
| Abbott Laboratories | $42.29 | 2022-2023 | Proclaim |
| Actelion Pharmaceuticals US, INC. | $20.97 | 2023 | Opsumit, Uptravi |
| Exact Sciences Corporation | $19.97 | 2024 | Cologuard Collection Kit |
| Cranial Technologies, INC | $14.38 | 2024 | Doc Band |
| Pfizer INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Abela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.